Skip to main content
. 2016 Apr 22;95(16):e3417. doi: 10.1097/MD.0000000000003417

FIGURE 4.

FIGURE 4

Interleukin (IL)-6 levels. Circulating IL-6 levels in patients with infliximab (IFX) treatment failure due to nonimmune pharmacokinetics (PK) (n = 18) or pharmacodynamics (PD) (n = 8) at treatment failure (week 0) and after 12 weeks of intensified IFX regimen. (∗) P < 0.05 by Wilcoxon signed-rank test. Lower limit of IL-6 quantification (LLOQ) was 3.1 pg/mL (dotted line), and values below LLOQ are arbitrarily set to 1.5 pg/mL and shown as gray (n = 9 and n = 2, respectively).